AF Anticoagulation in Liver Disease — EECC MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Liver disease creates a paradoxical state of both increased bleeding risk AND increased thrombotic risk; DOACs are generally avoided in Child-Pugh C and used with caution in Child-Pugh B; warfarin with careful INR monitoring or individual assessment at specialist centres is needed
Explanation lettering: E = shown as A · A = shown as B · D = shown as C · C = shown as D · B = shown as E
Liver disease and AF anticoagulation is complex: (1) the liver produces BOTH procoagulant factors (II, VII, IX, X, fibrinogen) AND anticoagulant factors (protein C, S, antithrombin) — advanced liver disease disrupts BOTH sides, creating a 'rebalanced' but fragile haemostatic state; (2) DOAC considerations by Child-Pugh class: A = generally safe; B = use with caution (rivaroxaban specifically contraindicated in Child-Pugh B/C; apixaban and edoxaban may be used cautiously); C = DOACs contraindicated (excluded from all trials, unpredictable pharmacokinetics); (3) warfarin challenges: baseline INR is already elevated in liver disease, making therapeutic monitoring difficult; (4) bleeding risk: portal hypertension causes varices (high GI bleeding risk), thrombocytopenia (splenic sequestration); (5) the 2024 ESC AF Guidelines recommend individualised assessment at specialist hepatology-cardiology centres. CHA₂DS₂-VA scoring may underestimate stroke risk in liver disease (liver disease independently increases thrombotic risk).
Reference: ESC (2024): AF Guidelines